Mutual of America Capital Management LLC Sells 9,047 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Mutual of America Capital Management LLC trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 358,819 shares of the company’s stock after selling 9,047 shares during the period. Mutual of America Capital Management LLC’s holdings in Roivant Sciences were worth $4,245,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ROIV. Gladius Capital Management LP bought a new stake in shares of Roivant Sciences during the 3rd quarter worth $35,000. US Bancorp DE boosted its holdings in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after buying an additional 1,288 shares during the period. Quarry LP boosted its holdings in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after buying an additional 2,500 shares during the period. Finally, Blue Trust Inc. boosted its holdings in shares of Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock worth $91,000 after buying an additional 6,667 shares during the period. 64.76% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ROIV. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $18.08.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $10.70 on Thursday. Roivant Sciences Ltd. has a 52-week low of $9.76 and a 52-week high of $13.06. The stock has a market cap of $7.63 billion, a price-to-earnings ratio of -71.33 and a beta of 1.25. The firm has a fifty day moving average of $11.01 and a 200-day moving average of $11.57.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, sell-side analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Insider Activity

In other news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was acquired at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the transaction, the director now directly owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now owns 163,264 shares of the company’s stock, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 2,388,170 shares of company stock worth $27,612,299. 7.90% of the stock is currently owned by corporate insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.